Abstract
Immune checkpoint inhibitors (ICIs) are now widely used in monotherapy or in combination with chemotherapy in advanced non-small cell lung cancer (NSCLC), and in combination with chemotherapy in advanced small-cell lung cancer (SCLC). However, few data are currently available concerning the acquired resistance mechanisms to ICIs in lung cancer. There is therefore a need for systematic prospective collection of tumor samples for histological and molecular analyses at the time of progression.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
